Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

The trial is testing epcoritamab, a biological treatment administered subcutaneously, either as a monotherapy or in combination with standard-of-care (SOC) chemotherapy agents. The goal is to ...

Epcoritamab is an IgG1-bispecific antibody engineered to bind simultaneously to CD3 on T cells and CD20 on B cells, facilitating T-cell–mediated destruction of CD20+ cells. 2 It was developed ...

Epcoritamab is part of a class of drugs called bispecific T-cell engagers. In essence, epcoritamab has 2 binding epitopes, 1 to CD20, which would target malignant or normal B cells, and the other ...

Epcoritamab in combination with R 2 is being studied further in the ongoing, randomized, Phase 3 EPCORE FL-1 trial (NCT05409066). About the EPCORE® NHL-2 Trial ...

Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY™ (epcoritamab-bysp) delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median ...

Genmab shares were 6% higher, at $22.72 a share, after the company reported positive results of a Phase 3 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide in ...

It was hypothesized that the immunomodulatory effects of lenalidomide might enhance the activity of epcoritamab,” Merryman said. The epcoritamab plus R2 combination was tested in 110 patients.

H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The ...